Prevalence of Human Immunodeficiency Virus Infection among Tuberculosis Patients at Infectious Disease Hospital, Kano State, Nigeria
DOI:
https://doi.org/10.47430/ujmr.2052.006Keywords:
Tuberculosis, Human Immunodeficiency Virus, Infection, Prevalence, Drug SusceptibilityAbstract
The epidemic of Human Immunodeficiency Virus (HIV) and the emergence of drug resistant Mycobacterium tuberculosis strains have been recognized as the most important factors contributing to increasing resurgence of tuberculosis (TB). This study was conducted to determine the prevalence of HIV among tuberculosis patients and drug sensitivity pattern of some of the mycobacterial isolates. One hundred and sixty eight (168) sputum samples from tuberculosis patients attending Infectious Diseases Hospital, Kano were collected and processed for the presence of Mycobacteria. Blood samples of the patients were also screened for the presence of HIV. The drug susceptibility test (DST) was performed using the BACTEC Mycobacteria Growth Inhibitory Test (MGIT) M960 technique. Results revealed that out of the 168 patients studied 24 (14.29%) were TB and HIV co-infected and 135 (68.88%) were males while 61 (31.12%) were females (P = 0.001). Majority of the studied cases were of the age groups 15-24 years and 25-34 years (P = 0.001). Ten (58.82%) of the 17 isolates that were subjected to DST against the first-line anti-TB drugs (isoniazid, rifampicin, ethambutol, pyrazinamide) were found to be resistant against the various drugs to which they were tested; out of which 7 (41.17%) exhibited a primary drug resistance pattern, 3 (17.65%) exhibited acquired drug resistance pattern and 2 (11.74%) were multi-drug resistant TB. The highest drug resistance of 23.53% was recorded against isoniazid, followed by rifampicin, ethambutol and pyrazinamide each with a resistance of 17.65%. The study recommends screening of all TB patients for early diagnosis of HIV co-infection as well as conducting DST which will inform prompt management of the infected individuals and designing appropriate treatment schedule for effective TB/HV control as well as preventing transmission of drug resistant TB.
Downloads
References
Adjers-Koskela, K., and Katila, M. L. (2003). Susceptibility testing with manual Mycobacteria Growth Indicator Tube (MGIT) and MGIT 960 provides rapid and reliable verification of Multi-drug Resistant TB. Journal of Clinical Microbiology, 41 (3): 1235-9. doi:10.1128/jcm.41.3.1235-1239.2003.
https://doi.org/10.1128/JCM.41.3.1235-1239.2003
Alene, K. A., Viney, K., Moore, H. C., Wagaw,M. and Clements, A. C. A. (2019). Spatial patterns oftuberculosis and HIV co-infection in Ethiopia. PLoS ONE, 14 (12): e0226127.https://doi.org/10.1371/journal.pone. 0226127.
https://doi.org/10.1371/journal.pone.0226127
Aminu, A. I. and Habib, N. L. (2019). Studies on some immunological profile of patients infected with tuberculosis attending Infectious Diseases Hospital. Bayero Journal of Pure and Applied Sciences (Special Conference Edition November 2019), 12 (1): 5-12.http://dx.doi.org/10.4314/bajopas.v12 i1.12S.
https://doi.org/10.4314/bajopas.v12i1.2S
Awofala, A. A. and Ogundele, O. E. (2018). HIV epidemiology in Nigeria. Saudi Journal of Biological Sciences, 25: 697-703.http://dx.doi.org/10.1016/j.sjbs.2016. 03.006.
https://doi.org/10.1016/j.sjbs.2016.03.006
Campos, P. E., Suarez, P. G., Sanxhez, J., Zavala, D., Arevalo, J., Ticona, E., Nolan, C. M., Hooton, T. M. and Holmes, K. K. (2003). Multi-drug resistant Mycobacterium tuberculosis in HIV infected persons, Peru. Emerging Infectious Diseases, 9 (12): 1571-1578. https://dx.doi.org/10.3201/eid0912.02 0731.
https://doi.org/10.3201/eid0912.020731
Chanda-Kapata, P., Kapata, N., Klinkenberg, E., Grobusch, M. P. and Cobelens, F. (2017). The prevalence of HIV among adults with pulmonary TB at a population level in Zambia. Bio Med Central Infectious Diseases, 17:236.DOI 10.1186/s12879-017-2345-5.
https://doi.org/10.1186/s12879-017-2345-5
da Silva, P. E. and Palomino, J. C. (2011). Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. Journal of Antimicrobial Chemotherapy, 66 (7): 1417-30. DOI: 10.1111/j.1574-695X.2011.00831.x.
https://doi.org/10.1111/j.1574-695X.2011.00831.x
Davila, S., Hibberd, M. L., Dass, R. H., Wong,H. E. E., Sahiratmadja, E., Bonnard, C., Alisjahbana, B., Szeszko, J. S., Balabanova, Y., Drobniewski, F., van Crevel, R., van de Vosse, E., Nejentsev, S., Ottenhoff, T. H. M. andSeielstad, M. (2008). Genetic association and expression studies indicate a role of Toll-Like Receptor 8 in pulmonary tuberculosis. PLOS Genetics, 4 (10): e1000218https://doi.org/10.1371/journal.pgen.1 000218.
https://doi.org/10.1371/journal.pgen.1000218
Gunda, D. W., Maganga, C. S., Nkandala, I., Kilonzo, S. B. Mpondo, B. C. Shao, E. R. and Kalluvya, S. E. (2018). Prevalence and risk factors of active TB among adult HIV patients receiving ART in Northwestern Tanzania: Aretrospective cohort study. Canadian Journal of Infectious Diseases and Medical Microbiology, 2018 (Article ID 1346104): 1-7.https://doi.org/10.1155/2018/1346104
https://doi.org/10.1155/2018/1346104
Jain, A. and Mondal, R. (2008). Extensively drug-resistant tuberculosis: current challenges and threats: Federation of European Microbiological Societies Immunology and Medical Microbiology, 53 (2): 145-150. DOI:10.1111/j.1574-695X.2008.00400.x.
https://doi.org/10.1111/j.1574-695X.2008.00400.x
Kent, P. T. and Kubica, G. P. (1985). Anti- tuberculosis chemotherapy and drug susceptibility, Public health Mycobacteriology: A guide for the level III laboratory. Center for Disease Control and Prevention, 1: 159-84.
Manjareekaa, I., and Nanda, S. (2013). Prevalence of HIV infection among tuberculosis patients in Eastern India. Journal of Infection and Public Health, 6: 358-362 6: 358-362http://dx.doi.org/10.1016/j.jiph.2013. 04.004.
https://doi.org/10.1016/j.jiph.2013.04.004
National Committee for Clinical Laboratory Standards (NCCLS). (2011). Susceptibility of Mycobacteria, Norcadia, and Actinomycetes 2nd ed. Tentative Standards M24-T2 Wayne, P.A.7.
National Institute for Pharmaceutical Research and Development (NIPRD) (2005). Manual for conducting drug sensitivity pattern of mycobacterial isolates, NIPRD/SOP#1.
National Tuberculosis and Leprosy Control Programmes (NTBLCP) (2011): Manual on Technical SOPs for Tuberculosis Laboratories in Nigeria.
Neyrolles, O. and Quintana-Murci, L. (2009). Sexual inequality in Tuberculosis. PLoS Medicine, 6 (12):e1000199. DOI:10.1371/journal.pmed.1000199.
https://doi.org/10.1371/journal.pmed.1000199
Oladeinde, B, H., Olley, M., Imade, O. S. and Onifade, A. A. (2014). Prevalence of HIV infection among patients withpulmonary tuberculosis in a rural tertiary hospital in Nigeria. Nigerian Journal of Experimental and Clinical Biosciences, 2: 90-4.http://www.njecbonline.org.
https://doi.org/10.4103/2348-0149.144843
Palmero, D., Ritacco, V., Ambroggi, M., Natiello, M., Barrera, L., Capone, L., Dambrosi, A., Di Lonardo, M., Isola, N., Poggi, S., Vescovo, M. and Abbate, E. (2003). Multidrug-Resistant Tuberculosis in HIV-Negative Patients, Buenos Aires, Argentina. Emerg Infect Dis, 9 (8): 965-969. doi: 10.3201/eid0908.020474
https://doi.org/10.3201/eid0908.020474
Ranti, K. O. Atilola O. G., Babalola T. V. and Komolafe O. I. (2016). Prevalence of HIV infection among tuberculosis patients in a teaching Hospital in South-west Nigeria: A four-year retrospective study. HIV & AIDS Review, 15: 136-140. http://dx.doi.org/10.1016/j.hivar.2016.11.001 1730-1270/.
https://doi.org/10.1016/j.hivar.2016.11.001
Scarparo, C., Ricordi, P., Ruggiero, G. and Piccoli, P. (2004). Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method. Journal of Clinical Microbiology, 42 (3): 1109-14. doi: 10.1128/jcm.42.3.1109-1114.2004.
https://doi.org/10.1128/JCM.42.3.1109-1114.2004
Wang, L., Liu, W., Wang, L., Wang, Y. and Wu,Z. (2010). HIV Prevalence among Pulmonary Tuberculosis Patients in Guangxi, China. Journal ofAcquired Immune Deficiency Syndrome, 53 (Suppl 1): S61. doi:10.1097/QAI.0b013e3181c7db2e.
https://doi.org/10.1097/QAI.0b013e3181c7db2e
World Health Organization (WHO) (2019): Global Tuberculosis Report, Executive Summary. WHO/CDS/TB/2019.23.https://www.w ho.int/tb/publications/global_report/G raphicExecutiveSummary.pdf?ua=1.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 UMYU Journal of Microbiology Research
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.